Dalbavancin two dose regimen for the treatment of prosthetic joint infections: new possible options for difficult to treat infectious diseases

Infect Dis (Lond). 2021 Jun;53(6):473-475. doi: 10.1080/23744235.2021.1893898. Epub 2021 Mar 9.

Authors

Affiliations

¹ Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University Hospital of Sassari, Sassari, Italy.
² Department of Chemistry and Pharmacy, University of Sassari, Sassari, Italy.
³ Department of Biomedical Sciences, University of Sassari, Sassari, Italy.
⁴ Meditteranean Center for Disease Control, Sassari, Italy.

PMID: 33689547
DOI: 10.1080/23744235.2021.1893898

No abstract available

Publication types

Letter

MeSH terms

Anti-Bacterial Agents / therapeutic use
Communicable Diseases* / drug therapy
Humans
Staphylococcal Infections* / drug therapy
Teicoplanin / analogs & derivatives

Substances

Anti-Bacterial Agents
Teicoplanin
dalbavancin